Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Int J Antimicrob Agents ; 28(5): 472-6, 2006 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-17046209

RESUMEN

A national multicentre prevalence study was undertaken to determine the bacterial strains associated with mild-to-moderate acute exacerbations of chronic bronchitis (AECB) in the primary care setting and the susceptibility of isolated pathogens to different antimicrobials usually prescribed to these patients. All samples were processed by a central reference laboratory. Microdilution tests were carried out to establish the minimum inhibitory concentration (MIC) of various antimicrobials. A double-disk test was performed to establish the macrolide resistance phenotype in Streptococcus pneumoniae. Tests to detect the presence of beta-lactamase in Haemophilus influenzae and Moraxella catarrhalis and polymerase chain reaction to detect the presence of ermB and mefA genes in S. pneumoniae isolates were also performed. A total of 1537 patients were included in the trial and 468 microorganisms were isolated from sputum samples, with the most frequent isolates being S. pneumoniae (34.8%), M. catarrhalis (23.9%) and H. influenzae (12.6%). Resistance rates of pneumococci were 47.2% for penicillin, 1.2% for amoxicillin, 34.3% for macrolides (87.5% of which showed high-level resistance), 13.6% for cefuroxime/axetil and 4.2% for levofloxacin. No bacterial isolates showed resistance to telithromycin. Empirical antibiotic treatment was prescribed to 98.3% of patients, including macrolides to 36.6%, amoxicillin with or without clavulanic acid to 32.3% and fluoroquinolones to 16.1%. In conclusion, S. pneumoniae was the most frequently isolated bacteria in patients with mild-to-moderate AECB. Despite the high rates of resistance of pneumococci to macrolides, they continue to be the most widely used antibiotics in primary care to treat AECB.


Asunto(s)
Antibacterianos/uso terapéutico , Bronquitis Crónica/tratamiento farmacológico , Farmacorresistencia Bacteriana/genética , Esputo/microbiología , Adulto , Anciano , Antibacterianos/farmacología , Proteínas Bacterianas/genética , Bronquitis Crónica/epidemiología , Bronquitis Crónica/microbiología , Estudios Transversales , Femenino , Haemophilus influenzae/efectos de los fármacos , Haemophilus influenzae/genética , Haemophilus influenzae/aislamiento & purificación , Humanos , Masculino , Proteínas de la Membrana/genética , Metiltransferasas/genética , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Moraxella catarrhalis/efectos de los fármacos , Moraxella catarrhalis/genética , Moraxella catarrhalis/aislamiento & purificación , Prevalencia , Atención Primaria de Salud/estadística & datos numéricos , España/epidemiología , Streptococcus pneumoniae/efectos de los fármacos , Streptococcus pneumoniae/genética , Streptococcus pneumoniae/aislamiento & purificación
2.
Eur J Clin Microbiol Infect Dis ; 17(6): 420-3, 1998 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-9758285

RESUMEN

The in vivo efficacy of trovafloxacin, intraperitoneally administered as alatrofloxacin (CP-116,517), was assessed and compared with that of erythromycin, alone or in combination with rifampicin, in a model of Legionella pneumophila pneumonia in guinea pigs. Trovafloxacin (5 mg/kg administered as alatrofloxacin once daily for 7 days) gave a survival rate of 100% in infected animals. Clearance of bacteria and of bacteria-induced lesions from lungs was achieved by day 6 post-inoculation. The lungs of trovafloxacin-treated animals remained free of bacteria at day 28 post-challenge. Trovafloxacin proved as effective as erythromycin administered intraperitoneally, but was superior to erythromycin alone. or in combination with rifampicin, when given orally.


Asunto(s)
Antiinfecciosos/uso terapéutico , Fluoroquinolonas , Enfermedad de los Legionarios/tratamiento farmacológico , Profármacos/uso terapéutico , Administración Oral , Animales , Antiinfecciosos/administración & dosificación , Antiinfecciosos/farmacología , Evaluación Preclínica de Medicamentos , Quimioterapia Combinada/administración & dosificación , Quimioterapia Combinada/uso terapéutico , Eritromicina/administración & dosificación , Eritromicina/uso terapéutico , Femenino , Cobayas , Inyecciones Intraperitoneales , Legionella pneumophila/efectos de los fármacos , Enfermedad de los Legionarios/microbiología , Pulmón/microbiología , Pruebas de Sensibilidad Microbiana , Distribución Aleatoria , Rifampin/administración & dosificación , Rifampin/uso terapéutico
3.
J Gen Microbiol ; 136(12): 2421-32, 1990 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-2079629

RESUMEN

Candida albicans ATCC 26555 switched at high frequency (10(-1) to 10(-3)) between several phenotypes identified by colony morphology on a defined mineral amino-acid-containing agar medium supplemented with arginine and zinc (LAZ medium). When cells taken from colonies exhibiting distinct morphologies were plated directly onto LAZ agar, spontaneous conversion to all the variant phenotypes occurred at combined frequencies of 2.1 x 10(-1) to 9.5 x 10(-3). However, when cells taken from the different colonial phenotypes were plated directly onto an undefined medium (yeast extract/peptone/dextrose; YPD medium), or first incubated in liquid YPD medium and then cloned on YPD agar, all colonies observed exhibited the same phenotype (smooth-white). When cells from the smooth-white colonies were plated as clones on LAZ agar, the original switch phenotype reappeared. These results suggest that environmental conditions such as the growth medium (and possibly the temperature) influence switching by suppressing phenotype expression, but have no effect on genotype. The variant colony morphologies also appeared to be associated with differences in the relative proportions of yeast and mycelial cells. Zymolyase digests of wall preparations obtained from cells belonging to different colonial phenotypes were analysed by SDS-PAGE. After blotting to nitrocellulose paper, the mannoproteins were stained with Concanavalin A, with a polyclonal antiserum enriched in antibodies against mycelium-specific wall components, and with a monoclonal antibody raised against a high-molecular-mass mannoprotein band (260 kDa) specific to the walls of mycelial cells. The results suggest that phenotypic switching might be associated with changes in the degree of glycosylation in high-molecular-mass mannoproteins, or in the way these mannoproteins are bound to other cell wall components.


Asunto(s)
Candida albicans/citología , Pared Celular/metabolismo , Proteínas Fúngicas/metabolismo , Glicoproteínas de Membrana/metabolismo , Candida albicans/crecimiento & desarrollo , Candida albicans/metabolismo , Concanavalina A , Medios de Cultivo , Electroforesis en Gel de Poliacrilamida , Proteínas Fúngicas/aislamiento & purificación , Hidrolasas/metabolismo , Glicoproteínas de Membrana/aislamiento & purificación , Fenotipo , Temperatura
4.
Mycopathologia ; 89(3): 135-8, 1985 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-3887174

RESUMEN

An experimental Keratitis study of Aspergillus fumigatus was performed in 130 rabbits divided into 12 groups of ten animals each. Three antifungal drugs (myconazole, amphotericin B and pimaricin) were tested using two procedures (topical drops and subconjunctival injections) and two different concentrations (500 and 10 000 times the MIC). In each case, the drugs were applied every 3 h starting 14 h after inoculation. Miconazole was useful at 10 mg/ml concentration by topical drops and subconjunctival injections, but was less useful at 5 mg/ml. Amphotericin B was useful at 5 mg/ml concentration by topical drops and less useful at 2 mg/ml. No differences were found between the two concentrations by subconjunctival administration. Pimaricin was useful by topical drops at 50 mg/ml concentration and less useful at 10 mg/ml as well as by subconjunctival injections.


Asunto(s)
Aspergilosis/tratamiento farmacológico , Queratitis/tratamiento farmacológico , Administración Tópica , Anfotericina B/administración & dosificación , Animales , Aspergillus fumigatus , Conjuntiva , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Femenino , Inyecciones , Masculino , Miconazol/administración & dosificación , Natamicina/administración & dosificación , Conejos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA